MedTrace Logo

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

NCT06380907 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2024-11-05

No results posted yet for this study

Summary

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

Conditions

Interventions

DRUG

ZL-1102 1% w/w gel BID for 16 weeks

ZL-1102 1% w/w gel BID for 16 weeks

DRUG

ZL-1102 3% w/w gel BID for 16 weeks

ZL-1102 3% w/w gel BID for 16 weeks

DRUG

ZL-1102 3% w/w gel QD for 16 weeks

ZL-1102 3% w/w gel QD for 16 weeks

DRUG

Placebo ZL-1102 0% w/w gel BID for 16 weeks

Vehicle 0% w/w gel BID for 16 weeks

DRUG

Placebo ZL-1102 0% w/w gel QD for 16 weeks

Vehicle 0% w/w gel QD for 16 weeks

Sponsors & Collaborators

  • Zai Lab (US) LLC

    collaborator INDUSTRY

  • Zai Lab (Hong Kong), Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-22
Primary Completion
2026-02-28
Completion
2026-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06380907 on ClinicalTrials.gov